Funding profile · Surgical soft tissue

TYBR Health

Four Form D notices trace a Houston device company from a $710,000 angel seed in 2020 to a $30 million Series A in 2026. Half of that Series A was sold when the notice was filed.

$30.0MSeries A announced July 21, 2026, led by Vensana and Mutual Capital
$14.4MSold of that $30.0M offering at the July 22, 2026 filing
$22.2MTotal equity sold across the Form D record since 2020
$782KNIH SBIR Phase I grants, non-dilutive, about 3% of capital on record

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Nov 2020 First seed $709,999 sold of $1,250,000 8 Form D
Winter 2022 Y Combinator batch Not disclosed Y Combinator YC
2021 to 2022 NIH SBIR Phase I, three awards $782,475 NIDDK and NIAMS NIH
Oct 2024 Seed Prime Preferred, in market $2,000,000 target, $700,000 committed Mayo Clinic Ventures named among them Forum listing
Jan 2025 Seed Prime Preferred, first sale Jan 17, 2025 $1,084,679 sold of $2,000,000 8 Form D
Nov 2025 Same offering, amended upward $7,142,974 sold of $7,918,951 50 Form D/A
Jul 2026 Series A $30,000,000 announced; $14,354,342 sold at filing 12; Vensana, Mutual Capital, Neovate Form D + release

What the filings show

TYBR Health, Inc. · Form D · filed Jul 22, 2026

First sale
Jul 9, 2026
Offered
$30,000,000 equity
Sold
$14,354,342 · $15,645,658 remaining
Investors
12 · average about $1,196,200
Exemption
Rule 506(b)
Related persons
Timothy J. Keane Jr. and Alex Smith (executive officers, directors); Aaron Smith, Jeffrey Tyber, Greg Banker, Liz Zambory, Toby Hamilton (directors)
Filing
SEC EDGAR, CIK 0001835188

TYBR Health, Inc. · Form D/A · filed Nov 26, 2025

First sale
Jan 17, 2025
Offered
$7,918,951 equity
Sold
$7,142,974 · $775,977 remaining
Investors
50 · average about $142,860
Exemption
Rule 506(b)
Related persons
Timothy J. Keane (executive officer, director); Alex Smith, Tom Dugan, Toby Hamilton, Jeffrey Tyber (directors)
Filing
SEC EDGAR, CIK 0001835188

TYBR Health, Inc. · Form D · filed Jan 31, 2025

First sale
Jan 17, 2025
Offered
$2,000,000 equity
Sold
$1,084,679 · $915,321 remaining
Investors
8 · average about $135,585
Exemption
Rule 506(b)
Related persons
Timothy Keane (executive officer, director); Alex Smith and Tom Dugan (directors)
Filing
SEC EDGAR, CIK 0001835188

TYBR Health, Inc. · Form D · filed Dec 9, 2020

First sale
Nov 23, 2020
Offered
$1,250,000 equity
Sold
$709,999 · $540,001 remaining
Investors
8 · average about $88,750
Exemption
Rule 506(b)
Related persons
Timothy J. Keane, Jr. and Alex Smith (executive officers, directors, promoters); Cooper Collins (director); Stephen Ramon (officer)
Filing
SEC EDGAR, CIK 0001835188

Reading the filings

  1. The Series A was half sold when it was announced.The release of July 21, 2026 calls it a $30 million financing. The notice filed the next day reports $14,354,342 sold and $15,645,658 remaining, from 12 investors, about $1,196,200 each. The $30,000,000 is an offering ceiling, not cash received.
  2. The seed round quadrupled and changed character.The January 2025 notice offered $2,000,000 and reported $1,084,679 from 8 investors. The November 2025 amendment keeps the same first sale date but lifts the offering to $7,918,951 and reports $7,142,974 from 50 investors. Forty-two investors were added at about $144,000 each: an extension filled by individuals and small vehicles, not a second institutional round.
  3. Form D undercounts the early years by roughly $3.2 million.An investor forum listing in October 2024 put money raised to date at $3.9 million of equity plus $750,000 non-dilutive. EDGAR shows only $709,999 of equity sold before 2025. Notes and SAFEs sold under Section 4(a)(2) file no Form D, so the gap is ordinary, but the public record starts well behind the company total.
  4. The board turns over, and one seat appears before it is announced.Jeffrey Tyber is listed as a director on the amendment filed November 26, 2025; his appointment was announced on January 12, 2026, seven weeks later. Cooper Collins and Stephen Ramon appear on the 2020 notice and on none after it. Tom Dugan sits on both 2025 filings and not the 2026 one, where Greg Banker of Vensana and Liz Zambory of Mutual Capital appear, matching the release.
  5. Grant money has become a rounding error.$782,475 of NIH awards against $22,207,315 of equity sold is about 3 percent. In the company’s own October 2024 figures, non-dilutive money was roughly 16 percent. The mix has shifted to venture capital, and with it the pressure to show revenue.

Commercial signals

Signal Detail Source type
Regulatory 510(k) K250109, cleared Jun 6, 2025, product code OWY: a collagen surgical mesh “For reinforcement of soft tissue where weakness exists in tendon repair.” No adhesion prevention claim and no abdominal indication on the FDA record. Public record
Launch timing In June 2025 the company said sales would begin by the end of 2025. First US clinical use was announced Jan 5, 2026. Company-stated
Use to date Hand, wrist, shoulder, foot and ankle, and sports medicine cases. No customer names, unit counts or revenue disclosed. Company-stated
Clinical evidence Two peer-reviewed preclinical papers, Oct 2025 and Mar 2026. Australian tenolysis study, first patients Sep 2025, no results, no registry entry found. Public record
Strategic backers Mayo Clinic Ventures named among seed investors committed in an Oct 2024 forum listing, and not confirmed in any release since. Investor-stated

What to watch

  • An amended Form D showing whether the remaining $15,645,658 is sold.
  • Any confirmation of Mayo Clinic Ventures, named as committed in 2024 and unmentioned since.
  • The first revenue, unit or named-account disclosure.
  • Results from the Australian study, and any second FDA submission widening what can be claimed.

The TYBR Health story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Allotrope Medical: Also in Medical Devices. A Houston surgical resident built a box that makes the ureter move on command, cleared it in 2020, and sold the company in 2023
  • Revolve Surgical: Also in Medical Devices. A Toronto company building a laparoscopic robot that clamps to the operating table instead of filling the room
  • inSoma Bio: Also in Medical Devices. A liquid protein that sets into a scaffold at body temperature, injected together with a patient’s own liposuctioned fat
  • Andromeda Surgical: Also in Medical Devices. A tablet-driven robot that guides urologists through one of the hardest operations in their specialty

Sources

  1. Public recordForm D, TYBR Health, Inc., CIK 0001835188SEC · Dec 9, 2020
  2. Public recordForm D and Form D/A, TYBR Health, Inc.SEC · Jan 31 and Nov 26, 2025
  3. Public recordForm D, TYBR Health, Inc.SEC · Jul 22, 2026
  4. Public recordNIH RePORTER awards R43DK127897, R43DK133012 and R43AR079966NIDDK and NIAMS · FY2021 to FY2022
  5. Public record510(k) record K250109 and product classification code OWYFDA · Jun 6, 2025
  6. IndependentHouston startup raises $30M to scale surgical healing gelInnovationMap · Jul 28, 2026
  7. IndependentMedtech Startups tracker entryLife Science Intelligence · Dec 2020
  8. IndependentKeiretsu Forum, TYBR Health investor session listingGeorgia Tech Research · Oct 2024
  9. Company$30 million Series A financingPR Newswire · Jul 21, 2026
  10. CompanyJeff Tyber appointed to the boardPR Newswire · Jan 12, 2026
  11. CompanyFirst U.S. clinical use of the B3 GEL SystemPR Newswire · Jan 5, 2026

Compiled from SEC, NIH and FDA public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in TYBR Health. This page is not an offer to sell or a recommendation to buy any security.